Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Pfizer Inc (PFE) Price & Performance

Mondelez International (MDLZ) trades at $59.38, down 0.4% with bearish technical signals but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.73 beating expectations of $0.68. Revenue reached $38.54 billion in 2025, with an 8.86% net income margin and solid cash flow generation of $795 million. Analyst consensus remains strongly bullish with a $70.29 price target, representing 18% upside potential from current levels.

MDLZ presents a compelling investment case with consistent earnings outperformance, attractive dividend yield, and strong brand portfolio. However, investors face risks from cocoa cost volatility, competitive pressures, and margin compression. The stock's current valuation at 21.75 P/E offers reasonable entry point for long-term investors seeking defensive exposure in consumer staples with global growth potential.

Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.

The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.